Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
ConclusionIn this heavily pretreated population including everolimus, fulvestrant plus palbociclib provides an mPFS of 5.8 months with the same magnitude of benefit for fulvestrant-pretreated patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | Hormones | Thrombocytopenia